Biotek-snakken — Marts 2024
-
Where Will Viking Therapeutics Stock Be in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight loss drug VK2735 provided a huge catalys https://www.proinvestor.com/investornyt/1135788/where-will-viking-therapeutics-stock-be-in-10-years
-
Is Viking Therapeutics Stock a Millionaire Maker? https://www.proinvestor.com/investornyt/1135925/is-viking-therapeutics-stock-a-millionaire-maker
-
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? https://www.proinvestor.com/investornyt/1136593/best-obesity-drug-stock-eli-lilly-novo-nordisk-or-viking-therapeutics
-
-
Zai Lab Partner Novocure's Metis Phase 3 Trial Meets Primary Endpoint In Brain Metastases https://www.proinvestor.com/investornyt/1137338/zai-lab-partner-novocures-metis-phase-3-trial-meets-primary-endpoint-in-brain-metastases
-
Aldeyra preps rebound bid for dry-eye hopeful reproxalap https://firstwordpharma.com/story/5841474?from=article
-
Aeovian moves seizure candidate into the clinic, raises $50M
AV078 is an mTORC1 inhibitor in development for tuberous sclerosis complex (TSC) epilepsy. https://firstwordpharma.com/story/5841451?from=article -
Akebia gets FDA approval of renal anaemia therapy Vafseo https://firstwordpharma.com/story/5841297?from=article
-
Arcadia Biosciences (RKDA) Reports Q4 Loss, Misses Revenue Estimates https://www.proinvestor.com/investornyt/1138130/arcadia-biosciences-rkda-reports-q4-loss-misses-revenue-estimates
-
NeuroBo Pharma offentliggør regnskabsresultat 2023 og forventninger til 2024. Lovende data mht. DA-1726 (fedme) og har likvider t.o.m. 2024. Financieringsbehov på sigt. https://www.neurobopharma.com/news-releases/news-release-details/neurobo-pharmaceuticals-reports-year-end-2023-financial-results
-
Applied Therapeutics Says FDA Extends Review Period Of NDA For Govorestat https://www.proinvestor.com/investornyt/1138140/applied-therapeutics-says-fda-extends-review-period-of-nda-for-govorestat
-
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals https://www.proinvestor.com/investornyt/1138230/better-buy-viking-therapeutics-vs-madrigal-pharmaceuticals
-
Why Viking Therapeutics Stock Was Rocketing Higher This Week https://www.proinvestor.com/investornyt/1138232/why-viking-therapeutics-stock-was-rocketing-higher-this-week
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind